Expansion of lipid analysis services based on LipoSEARCH

「Revenue from this service declined significantly year on year because there were no sizable domestic or overseas testing projects related to the blood lipoprotein profiling service “LipoSEARCH®,” and the number of clinical laboratory tests decreased.」

「Revenue from this service declined significantly year on year because there were no sizable domestic or overseas testing projects related to the blood lipoprotein profiling service “LipoSEARCH®,” and the number of clinical laboratory tests decreased.」

「Revenue from the service declined 49.1% year on year to ¥16.158 million because there were no sizable domestic or overseas tests related to the blood lipoprotein profiling service LipoSEARCH® and the number of clinical laboratory service tests decreased.」

「Revenue from testing related to the blood lipoprotein profiling service LipoSEARCH® and clinical laboratory services increased year on year, despite a service suspension of approximately 1 month due to the consolidation of facilities from the Akita Testing Center to the Fujioka Research Institute. Overseas revenue increased.」

「Clinical laboratory services declined, but revenue from testing related to the blood lipoprotein profiling service LipoSEARCH increased after revenue from a sizable project was recognized. As a result, total service revenue increased 6.9% year on year to ¥31.715 million.」

「Although revenue was recognized from a medium-sized project in testing related to the blood lipoprotein profiling service LipoSEARCH, orders declined overall and revenue came in below the previous year's level.」

「Testing and clinical laboratory services related to the blood lipoprotein profiling service LipoSEARCH came in slightly below the previous year's level.」

「Testing and clinical laboratory services related to the blood lipoprotein profiling service LipoSEARCH came in slightly below the previous year's level.」

「Testing related to the blood lipoprotein profiling service LipoSEARCH stagnated, and the number of sizable projects declined. As a result, revenue from the service was ¥64.265 million, down 25.3% year on year.」

「In the testing services business, tests related to the blood lipoprotein profiling service LipoSEARCH stagnated and declined year on year amid the COVID-19 pandemic. Meanwhile, revenue from contract measurement services using the Company's ELISA kits at clinical laboratories increased.」

「In the testing services business, tests related to the blood lipoprotein profiling service LipoSEARCH stagnated and declined year on year amid the COVID-19 pandemic. Meanwhile, revenue from contract measurement services using the Company's ELISA kits at clinical laboratories increased.」

「In the testing services business, tests related to the blood lipoprotein profiling service LipoSEARCH stagnated amid the COVID-19 pandemic, resulting in performance substantially below the previous year. Testing services 12,274 △5,461 △30.8 △4,832 △317 －」

「In the testing services business, SkyLight Biotech Co., Ltd. (SLB) was absorbed in a merger effective 1 November 2021. As a result of the merger, we began handling SLB's services, including LipoSEARCH, and will work to improve service quality further. At the same time, we expect to make sales and administrative personnel and physical resources more efficient and reduce expenses.」

「The merger will combine the technical capabilities accumulated by SLB, including LipoSEARCH, with Immuno-Biological Laboratories Co.,Ltd.'s comprehensive capabilities in the antibody field. We are confident that the resulting synergies will further improve service quality and reduce expenses by making personnel and physical resources in sales, administration and other functions more efficient.」

「In this business, the impact of the spread of COVID-19 was relatively significant in the previous fiscal year, but the business is recovering in the current fiscal year, and relatively large orders have begun to emerge for the core blood lipoprotein profiling service LipoSEARCH. As a result, segment revenue was ¥17.836 million, up 52.9% year on year, and the operating loss was ¥4.514 million, compared with an operating loss of ¥9.443 million in the same period of the previous year.」

「In addition, a paper comparing the gel-filtration HPLC method, the measurement method underlying LipoSEARCH, with its competing NMR method was published in February 2021. The paper concluded that particle-number analysis using gel-filtration HPLC more accurately reflected the lipid-improving effects of drugs than the NMR method.」

「Results for the 3 months of the third-quarter consolidated accounting period increased compared with the previous fiscal year, indicating a gradual recovery trend.」

「As with the diagnostics and reagents business, this business has been significantly affected by the spread of COVID-19, and activity at business partners related to the core blood lipoprotein profiling service LipoSEARCH has slowed considerably. Development of lipid disorder treatments by domestic pharmaceutical manufacturers has also declined, making it difficult to expect major orders of the kind received previously. Meanwhile, demand for the service is expected from food-related companies and CROs, and sales efforts in these fields are being strengthened.」

「This fiscal year, orders were centered on medium-sized to small projects, and the number of orders itself also declined, resulting in a substantial decrease in revenue from the previous year.」

「In this business, there were no major orders comparable to those received in the previous fiscal year for the core blood lipoprotein profiling service, LipoSEARCH, and orders were limited to medium-sized or small projects. As a result, revenue declined substantially year on year. Meanwhile, revenue from the animal service LipoTEST remained almost at the previous year's level. We are focusing on communication at the various conferences where we exhibit, continued approaches to our main customers, domestic pharmaceutical and food companies, expanding contract ELISA measurement services, entering the private-pay medical care field, and pursuing overseas licensing. As a result, segment revenue was ¥57.621 million, down 40.6% year on year, and the operating loss was ¥20.343 million, compared with operating profit of ¥11.393 million in the same period of the previous year.」

「In this business, no major orders comparable to those received in the previous fiscal year were secured for the core blood lipoprotein profiling service, LipoSEARCH, and orders were limited to relatively small projects. As a result, revenue declined year on year. Meanwhile, revenue from the animal service LipoTEST remained almost at the previous year's level. We are focusing on continued approaches to our main customers, domestic pharmaceutical and food companies, expanding contract ELISA measurement services, entering the private-pay medical care field, and pursuing overseas licensing. As a result, segment revenue was ¥38.645 million, down 46.0% year on year, and the operating loss was ¥12.534 million, compared with operating profit of ¥12.081 million in the same period of the previous year.」

「In this business, revenue declined year on year because the impact of a major order received in the previous fiscal year was substantial for the core blood lipoprotein profiling service, LipoSEARCH. Meanwhile, revenue from the animal service LipoTEST remained almost at the previous year's level. We are focusing on continued approaches to our main customers, domestic pharmaceutical and food companies, expanding contract ELISA measurement services, entering the private-pay medical care field, and pursuing overseas licensing.」

「A large order from a pharmaceutical company contributed to the detailed blood lipoprotein profiling tests provided through LipoSEARCH, the core service of this business. Transactions with food companies are also increasing, driven by the trend toward reducing metabolic syndrome. Lifestyle-related diseases are more serious overseas than in Japan, and measurement demand is expected to be higher. We are therefore considering licensing the service overseas to increase international revenue. We are currently building and testing the necessary system.」

「In this business, revenue was recognized for a major order for the core blood lipoprotein profiling service, LipoSEARCH. Going forward, we will continue to share sales activities with the diagnostics and reagents division, actively promote the services through conference exhibitions, and strengthen sales promotion in both markets. As a result, segment revenue was ¥96.944 million, up 13.8% year on year, and operating profit was ¥11.393 million, up 67.6% year on year.」

「In this business, the core blood lipoprotein profiling service, LipoSEARCH, secured a major order, which was recognized as revenue. Going forward, we will continue to share sales activities with the diagnostics and reagents division, actively promote the services through conference exhibitions, and strengthen sales promotion in both markets. As a result, segment revenue was ¥71.591 million, up 23.4% year on year, and operating profit was ¥12.081 million, up 147.6% year on year.」

「In this business, the core blood lipoprotein profiling service, LipoSEARCH, secured a major order and recognized part of it as revenue. This was the reason for the substantial year-on-year increase in revenue. Going forward, we will continue to share sales activities with the diagnostics and reagents business, actively promote the services through conference exhibitions, and strengthen sales promotion in both markets. As a result, segment revenue was ¥31.347 million, up 39.8% year on year, and the operating loss was ¥1.140 million, compared with an operating loss of ¥3.005 million in the same period of the previous year.」

「Preparations are under way to build a service for technology licensing overseas, particularly in the United States, where demand for cholesterol measurement is high. Compared with the LipoSEARCH service, the new service will be more limited in scope and capable of measuring samples simply, quickly and in large volumes.」

「The business actively conducted promotional activities through academic conference exhibitions in Japan and overseas, increased orders for large-scale projects and other engagements, and increased sales from the previous year. As a result, segment sales were ¥85,187 thousand, up 4.9% year on year, and operating profit was ¥6,796 thousand, compared with an operating loss of ¥12,790 thousand in the same period of the previous year.」

「The business actively conducted promotional activities through academic conference exhibitions in Japan and overseas, increased orders for large-scale projects and other engagements, and substantially increased sales from the previous year. As a result, segment sales were ¥58,030 thousand, up 33.5% year on year, and operating profit was ¥4,879 thousand, compared with an operating loss of ¥18,152 thousand in the same period of the previous year.」

「The testing business is also promoting LipoSEARCH, a detailed profiling measurement service for lipoproteins, which are proteins associated with lipids, as well as measurement services for cholesterol absorption and synthesis markers. By selling these measurement kits and contract measurement services and promoting them together, the Company expects to generate synergies.」

「The business strengthened promotional activities in both markets by sharing sales activities with the diagnostics and reagents division and jointly exhibiting at academic conferences in Japan and overseas. As a result, overseas sales increased substantially, while domestic sales declined due to the impact of the completion of a large-scale project and fell below the previous year’s level.」

「LipoSEARCH, the business’s core contract service for analyzing detailed profiling data on blood lipoprotein fractions using a system based on gel-filtration HPLC, actively conducted promotional activities at overseas academic conferences, expanded its overseas customer base and substantially increased sales. However, domestic sales declined due to the completion of a large-scale project from a domestic pharmaceutical company and other factors.」

「LipoSEARCH, the core contract service for analyzing detailed profiling data on blood lipoprotein fractions using a system based on gel-filtration HPLC, saw sales decline from the previous fiscal year due to the completion of a large-scale project from a domestic pharmaceutical company. Overseas, however, the Group began full-scale promotional activities at overseas academic conferences during the current fiscal year, and sales have increased steadily.」

「Sales declined from the previous fiscal year because a large-scale project from a domestic pharmaceutical company ended. However, the Company is actively conducting promotional activities overseas through academic conference exhibitions, raising expectations for securing orders going forward.」

「In the testing business, the Company is actively developing new analysis services centered on the keyword “Lipid” for customers engaged in R&D, a customer base developed through its lipoprotein profiling technology using high-performance liquid chromatography, its core technology, with the aim of substantially increasing average transaction prices.」